Comparative Pharmacology
Head-to-head clinical analysis: LEVOXYL versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOXYL versus TRIOSTAT.
LEVOXYL vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic thyroid hormone (T4) that is deiodinated to triiodothyronine (T3) in peripheral tissues, binding to thyroid hormone receptors in the nucleus and increasing metabolic rate, protein synthesis, and oxygen consumption.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 6-8 weeks based on TSH. Maintenance dose: 50-200 mcg orally once daily.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
6-7 days in euthyroid patients; prolonged in hypothyroidism (9-10 days), shortened in hyperthyroidism (3-4 days); clinical steady-state after 6-8 weeks of consistent dosing.
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal (30-50% as unchanged drug and conjugates); fecal (biliary, 20-40% as conjugates); total clearance approximates 1-2 L/day in euthyroid patients.
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone